1,629,182 Shares in Avalo Therapeutics, Inc. $AVTX Acquired by Braidwell LP

Braidwell LP acquired a new position in shares of Avalo Therapeutics, Inc. (NASDAQ:AVTX) during the second quarter, HoldingsChannel.com reports. The institutional investor acquired 1,629,182 shares of the company’s stock, valued at approximately $30,107,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Caligan Partners LP bought a new stake in shares of Avalo Therapeutics during the 3rd quarter valued at $10,592,000. Balyasny Asset Management L.P. bought a new position in shares of Avalo Therapeutics in the third quarter worth $10,390,000. Vanguard Group Inc. increased its position in shares of Avalo Therapeutics by 314.9% in the third quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after purchasing an additional 525,696 shares during the period. Millennium Management LLC increased its position in shares of Avalo Therapeutics by 380.2% in the fourth quarter. Millennium Management LLC now owns 659,979 shares of the company’s stock worth $11,985,000 after purchasing an additional 522,548 shares during the period. Finally, Seven Fleet Capital Management LP raised its stake in Avalo Therapeutics by 806.0% in the first quarter. Seven Fleet Capital Management LP now owns 573,883 shares of the company’s stock valued at $8,568,000 after purchasing an additional 510,540 shares in the last quarter. 87.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AVTX has been the subject of several recent analyst reports. Piper Sandler reaffirmed an “overweight” rating and set a $60.00 price objective (up from $48.00) on shares of Avalo Therapeutics in a research report on Monday, May 11th. Leerink Partners began coverage on shares of Avalo Therapeutics in a report on Monday, July 6th. They issued an “outperform” rating and a $38.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Avalo Therapeutics in a research report on Friday, July 24th. Citigroup restated an “outperform” rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Finally, Wall Street Zen raised shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $45.10.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock opened at $19.34 on Thursday. Avalo Therapeutics, Inc. has a 52 week low of $8.73 and a 52 week high of $24.27. The stock has a market capitalization of $1.04 billion, a P/E ratio of -4.43 and a beta of 0.78. The stock has a fifty day moving average of $19.08 and a 200-day moving average of $16.89.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.25). On average, research analysts forecast that Avalo Therapeutics, Inc. will post -2.59 earnings per share for the current year.

Insider Activity at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of the firm’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total value of $26,100.00. Following the sale, the insider directly owned 51,776 shares in the company, valued at approximately $931,968. This trade represents a 2.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,129 shares of company stock valued at $59,680 over the last three months. 4.46% of the stock is currently owned by corporate insiders.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.